RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 128 filers reported holding RECURSION PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.27 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $521,057 | +6.2% | 68,112 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $490,704 | +11.5% | 65,690 | -0.4% | 0.00% | 0.0% |
| Q1 2023 | $439,927 | -11.7% | 65,956 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $498,413 | -27.8% | 64,645 | -0.4% | 0.00% | -40.0% |
| Q3 2022 | $690,000 | +34.0% | 64,880 | +2.5% | 0.01% | +66.7% |
| Q2 2022 | $515,000 | +25.6% | 63,291 | +10.6% | 0.00% | +50.0% |
| Q1 2022 | $410,000 | -60.9% | 57,225 | -6.6% | 0.00% | -60.0% |
| Q4 2021 | $1,049,000 | +196.3% | 61,251 | +297.7% | 0.01% | +150.0% |
| Q3 2021 | $354,000 | -18.1% | 15,400 | +30.1% | 0.00% | +100.0% |
| Q2 2021 | $432,000 | – | 11,839 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CRV, LLC | 733,986 | $16,889,000 | 37.30% |
| MIC CAPITAL PARTNERS (PUBLIC) (US) IM, LLC | 1,388,889 | $31,958,000 | 5.87% |
| Yong Rong (HK) Asset Management Ltd | 377,000 | $8,675,000 | 5.69% |
| Samsara BioCapital, LLC | 752,939 | $17,325,000 | 2.72% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $34,728,000 | 2.04% |
| Spouting Rock Asset Management, LLC | 52,851 | $1,216,000 | 0.61% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 661,703 | $15,226,000 | 0.43% |
| Laurion Capital Management LP | 3,923,713 | $90,285,000 | 0.38% |
| Casdin Capital, LLC | 548,156 | $12,613,000 | 0.31% |
| Baillie Gifford | 22,061,374 | $507,632,000 | 0.27% |